UK markets open in 5 hours 55 minutes

Lysogene S.A. (0RNL.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.5600-0.0850 (-13.18%)
At close: 03:49PM GMT
Full screen
Previous close0.6450
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume100
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.61
PE ratio (TTM)N/A
EPS (TTM)-0.8070
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

    PARIS, November 18, 2022--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA. In subjects enrolled at <30 months of age (ancillary cohort, n=6), a statistically significant improvement in cognitive development compared to natural history (NH) was obser

  • Business Wire

    Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022

    PARIS, November 18, 2022--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that it will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

  • Business Wire

    Lysogene Reports its Cash Position as of 30 September 2022

    PARIS, October 13, 2022--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position of €6.1 million1 as of 30 September 2022 (compared to €7.7 million as of 30 June 2022).